Enoxaparin for prevention of unexplained recurrent miscarriage: a multicenter randomized double-blind placebo-controlled trial. - Wikidata - wikimedia - TriplyDB

Enoxaparin for prevention of unexplained recurrent miscarriage: a multicenter randomized double-blind placebo-controlled trial.

Enoxaparin for prevention of unexplained recurrent miscarriage: a multicenter randomized double-blind placebo-controlled trial.

http://www.wikidata.org/entity/Q35608806

about

Antithrombotic Treatment for Recurrent Miscarriage: Bayesian Network Meta-Analysis and Systematic Review Recurrent pregnancy loss: current perspectives Unexplained Recurrent Miscarriage and Recurrent Implantation Failure: Is There a Place for Immunomodulation?Precision Medicine in Assisted Conception: A Multicenter Observational Treatment Cohort Study of the Annexin A5 M2 Haplotype as a Biomarker for Antithrombotic Treatment to Improve Pregnancy Outcome Aspirin and heparin in pregnancy.The Role of Anticoagulants in the Prevention of Pregnancy Complications.Lessons From the EThIGII Trial: Proper Putative Benefit Assessment of Low-Molecular-Weight Heparin Treatment in M2/ANXA5 Haplotype Carriers.Heparin exerts anti-apoptotic effects on uterine explants by targeting the endocannabinoid system.ANXA5: a key to unlock the mystery of the spectrum of placental-mediated pregnancy complications?DNA fragmentation and the ultimate success of a pregnancy.Challenges of Anticoagulation Therapy in Pregnancy.Low-Molecular-Weight Heparin for the Treatment of Unexplained Recurrent Miscarriage With Negative Antiphospholipid Antibodies: A Randomized Controlled Trial.Paternal HLA-C is a risk factor in unexplained recurrent miscarriage.Effects of low molecular weight heparin on the polarization and cytokine profile of macrophages and T helper cells in vitro.

P2860

Q26777548-20E84357-C676-4955-8554-6BAF355DFB3E Q33713930-3D515F92-BB53-49E2-87F7-C7EB5A2ADBCD Q35915182-114BE67A-B8C4-4D2A-94D9-AD330986A411 Q37221358-243A5F42-2ACD-411B-82EE-2E99CF021876 Q38544097-178564E9-B96E-49F6-A6F5-2D59AAC9AA04 Q38632931-6638FB23-3EA5-4779-948F-83EF6284CA5B Q39599893-42798B81-0E5F-4335-BB74-C91636C7FDFA Q40629585-32A352E8-2B2C-46B7-B2E1-BFF3AF94469A Q42369323-A5A2FBFE-DBD3-4AAB-969B-E9ACFD2F644C Q42693600-3051E890-507D-42D8-9903-0930CE46B2F9 Q47252275-D52E593B-7DE8-41A2-9985-20ADA2625CA8 Q47278434-4B7A0532-A547-4F2C-9CF8-232D169F9595 Q48178955-706E7D72-723D-4F1F-8EBC-A18D6B45DEEE Q54979204-B3D03DA4-2520-47AF-9E16-FC872C62876A

P2860

Enoxaparin for prevention of unexplained recurrent miscarriage: a multicenter randomized double-blind placebo-controlled trial.

http://www.wikidata.org/entity/Q35608806

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Enoxaparin for prevention of u ...... lind placebo-controlled trial.

@ast

Enoxaparin for prevention of u ...... lind placebo-controlled trial.

@en

type

label

Enoxaparin for prevention of u ...... lind placebo-controlled trial.

@ast

Enoxaparin for prevention of u ...... lind placebo-controlled trial.

@en

prefLabel

Enoxaparin for prevention of u ...... lind placebo-controlled trial.

@ast

Enoxaparin for prevention of u ...... lind placebo-controlled trial.

@en

P1433

Q35608806-2E4E4F24-F161-47F2-A3EE-5CB1738AC9CC

P1476

Q35608806-1ACC5821-0043-4B10-89A5-751554FAC4B5

P2093

Q35608806-2EB47FB9-D424-4E8B-9249-CE59C321A1C0

Q35608806-40E9EE89-B25A-4666-9C3A-5BE35227859A

Q35608806-5B1AE734-ADD5-4606-AD94-0A119C93D6EE

Q35608806-A7A237FA-FACC-4F40-816E-6152AD085E20

Q35608806-A93597F7-C941-4B5F-B8AB-FEF73A59040D

Q35608806-AE63C428-FDEC-46AF-95B2-5981507BDEE0

Q35608806-BA4B6F11-7F01-49DD-B62D-E8173E471319

Q35608806-D2910D5E-D506-4D3D-995D-A9E94F77497F

Q35608806-DA5C1E6A-EBEF-4A92-91A4-4C4948A9CBC6

Q35608806-E3B4630F-6CE9-4DD8-BE46-58B0274157C0

P2860

Q35608806-27AC320B-6FC3-4CD5-9B8B-F69098B74F69

Q35608806-2ECBA74A-1E9A-476F-A88C-39C7D80D6668

Q35608806-3647C62A-66C2-48C4-8BE1-F260B5F6957A

Q35608806-3D198E13-EC9A-4D20-A6EA-CD7BD381AAEE

Q35608806-5560955A-E60E-4FF1-9F9F-5F9A4539A2E8

Q35608806-55816141-D6B2-4B6B-B201-F70CA29A994E

Q35608806-56F408BC-CE15-40CA-B7A3-5B12BA665E5E

Q35608806-63E7785F-CA33-42EB-80B1-8F4030108B63

Q35608806-66A9C756-E477-4ECE-92C1-BF92EF3001DA

Q35608806-66E9EC90-1D3C-4432-A2AD-36BF758C67B6

P304

Q35608806-438B48ED-15A0-461B-8D70-C2E7F268A276

P31

Q35608806-05AA34A8-4A5B-4416-9978-8D947E8BCC80

P356

Q35608806-53B167B7-2B20-47E6-811D-9C8850BCB027

P407

Q35608806-B56AE847-021B-4D02-A37D-7343B7025019

P433

Q35608806-6BFCE696-A633-4C94-9A1D-25858B4ACCAE

P478

Q35608806-16416496-8F05-4871-9780-621EF47F212B

P50

Q35608806-62FCA1F5-B992-4D2E-92AC-966BA919F046

Q35608806-7A0B8E99-AEDC-4633-A084-0D3AFA07C30D

P577

Q35608806-70704336-81DD-4F79-8BAD-9734E18E8EFC

P5875

Q35608806-7F53A301-506C-4671-81F1-2504174F36C0

P698

Q35608806-083C35B4-6287-4470-84E4-1CB990ABDEE7

P921

Q35608806-22D8BCCA-FA6C-41E1-8902-D458213D7302

Q35608806-9010555D-D959-411B-856E-D6602B4F1EDD

Q35608806-9CAC5BC4-E5F0-4CF0-8CAA-DEEF61D573CE

P932

Q35608806-447D893A-368F-453E-BA8F-FF9BA5187333

P356

BLOOD-2014-11-610857

P1433

P1476

Enoxaparin for prevention of u ...... blind placebo-controlled trial

@en

P2093

Caroline Bohec

http://www.w3.org/2001/XMLSchema#string

Christine Denoual-Ziad

http://www.w3.org/2001/XMLSchema#string

Céline Chauleur

http://www.w3.org/2001/XMLSchema#string

Dominique Mottier

http://www.w3.org/2001/XMLSchema#string

Frédéric Lecomte

http://www.w3.org/2001/XMLSchema#string

Gisèle Marhic

http://www.w3.org/2001/XMLSchema#string

Grégoire Le Gal

http://www.w3.org/2001/XMLSchema#string

Luc de Saint Martin

http://www.w3.org/2001/XMLSchema#string

Michel Heisert

http://www.w3.org/2001/XMLSchema#string

Serge Douvier

http://www.w3.org/2001/XMLSchema#string

P2860

Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia

Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder

Heparin and aspirin attenuate placental apoptosis in vitro: implications for early pregnancy failure

A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

Interaction revisited: the difference between two estimates

A proposed charter for clinical trial data monitoring committees: helping them to do their job well.

Aspirin plus heparin or aspirin alone in women with recurrent miscarriage.

Placental-specific IGF-II is a major modulator of placental and fetal growth.

Updated and revised nomenclature for description of early pregnancy events.

P304

2200-2205

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2014-11-610857

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

125

http://www.w3.org/2001/XMLSchema#string

P50

Florence Bretelle

Elisabeth Pasquier

P577

2015-01-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273954091

http://www.w3.org/2001/XMLSchema#string

P698

25636341

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

P932

4432556

http://www.w3.org/2001/XMLSchema#string